Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

doc2doc

- PMLiVE

After December slump, what’s in store for biotech in 2019?

Analysts say 2019 could be a "big year for proceeds if not for deal count"

- PMLiVE

Afinitor and Uptravi gain funding from NHS England

Rare disease treatments navigate tricky market access route

- PMLiVE

Orphan drugs dominate FDA’s record-breaking year

Gottlieb also promises to speed biosimilars and cell and gene therapies in 2019

- PMLiVE

Pharma’s confidence in Brexit deal falls as vote looms

Most EMIG members have little or no confidence in the government’s abilities to obtain a good deal

- PMLiVE

Positive disruption: getting to the bottom of big data

BLH speaks to Nicole Huyghe, founder and Managing Director of data science consultancy Boobook, about the growing need from businesses for data-driven decision making.

Blue Latitude Health

- PMLiVE

Pharma’s R&D productivity sinks to a new low

Returns at their lowest since 2010

- PMLiVE

Blow for J&J as court refuses to overturn talc verdict

Reuters and company at loggerheads over veracity of claims

- PMLiVE

Novartis buys CellforCure to bolster cell, gene therapy

Move would make existing partner an in-house capability

Highlights in haematologic malignancy from ASH 2018

The ASH congress is the most comprehensive haematology event of the year, over 5000 abstracts covering new developments in malignant and non-malignant haematology were presented. Here we focus on two...

Porterhouse Medical Group

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

- PMLiVE

Post-Brexit immigration policy has a critical missing piece

ABPI welcomes focus on skills, but UK must respond fast to skills gaps

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links